Patents by Inventor Annette M. Doherty
Annette M. Doherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6300501Abstract: Inhibitors of protein farnesyl transferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.Type: GrantFiled: November 2, 1998Date of Patent: October 9, 2001Assignee: Warner-Lambert CompanyInventors: Ellen M. Dobrusin, Annette M. Doherty, James S. Kaltenbronn, Daniele M. Leonard, Dennis J. McNamara, Judith Sebolt-Leopold, Kevon R. Shuler
-
Patent number: 6291678Abstract: A process for the preparation of novel keto heterocycle derivatives of basic natural and unnatural amino acids which affords products of high enantiomeric excess where a metalated heterocycle is reacted with N,O-dialkyl amide of an amino acid containing arylsulphonamide protected side chain amine in high chemical and optical yield as well as the novel compounds obtained by the process.Type: GrantFiled: December 11, 1998Date of Patent: September 18, 2001Assignee: Warner-Lambert CompanyInventors: Kent A. Berryman, Annette M. Doherty, Jeremy J. Edmunds, Janet S. Plummer
-
Patent number: 6281194Abstract: Novel inhibitors of protein farnesyltransferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer, restenosis, atherosclerosis, psoriasis and endometriosis.Type: GrantFiled: June 2, 1999Date of Patent: August 28, 2001Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, James S. Kaltenbronn, Daniele M. Leonard, Dennis J. McNamara
-
Patent number: 6124291Abstract: This invention relates to pyrrolo[1,2-a]pyrazine-1,4-diones of general formula: ##STR1## wherein B is carbonyl or methylene, R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen, alkyl, or substituted alkyl, A is a basic group, and Q is hydrogen or a keto heterocycle group.The compounds are inhibitors of serine proteases, typically thrombin, Factor Xa, and Factor VIIa, and are useful for treating and preventing thrombotic disorders.Type: GrantFiled: October 27, 1998Date of Patent: September 26, 2000Assignee: Warner-Lambert CompanyInventors: Kent A. Berryman, Annette M. Doherty, Jeremy J. Edmunds, M. Arshad Siddiqui
-
Patent number: 6008372Abstract: Substituted histidine compounds of formula (I) are described as well as methods for the preparation and pharamaceutical compositions of same, which are useful as inhibitors of protein famesyltransferase and for the treatment of proliferative diseases including cancer, restenosis, and psoriasis, and as antiviral agents.Type: GrantFiled: July 2, 1998Date of Patent: December 28, 1999Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, James S. Kaltenbronn, Daniele Leonard, John Quin, III, Jeffrey D. Scholten
-
Patent number: 5919780Abstract: Compounds of formula I ##STR1## wherein X is N or C--R.sup.9, Y is N--R.sup.10, CH.sub.2, O, S, SO, SO.sub.2, C.dbd.O or CH--OH,R is H or alkyl,R.sup.1 is heteroaryl,n is 1-5, andR.sup.2 -R.sup.10 are H or various substituents,are useful as inhibitors of protein farnesyl transferase and for the treatment of proliferative diseases including cancer, restenosis and psoriasis, and as antiviral agents.Type: GrantFiled: December 11, 1997Date of Patent: July 6, 1999Assignee: Warner Lambert CompanyInventors: Gary L. Bolton, Annette M Doherty, James S. Kaltenbronn, John Quin, III, Jeffrey D. Scholten, Judith Sebolt-Leopold, Harold Zinnes
-
Patent number: 5620981Abstract: 6-Aryl pyrido[2,3-d]pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.Type: GrantFiled: May 3, 1995Date of Patent: April 15, 1997Assignee: Warner-Lambert CompanyInventors: Clifton J. Blankley, Diane H. Boschelli, Annette M. Doherty, James M. Hamby, Sylvester Klutchko, Robert L. Panek
-
Patent number: 5610177Abstract: Novel acylated amino acids which are antagonists of endothelin are described. Methods for their preparation and pharmaceutical compositions containing them are also included. The compounds are expected to be useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, diabetes, head injury, and stroke.Type: GrantFiled: August 8, 1994Date of Patent: March 11, 1997Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Harriet W. Hamilton, James S. Kaltenbronn, John Quin, III
-
Patent number: 5599811Abstract: Novel benzothiazine dioxides which are antagonists of endothelin are described, as well as novel intermediates used in their preparation, methods for the preparation, and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.Type: GrantFiled: February 21, 1995Date of Patent: February 4, 1997Assignee: Warner-Lambert CompanyInventors: Kent A. Berryman, Amy M. Bunker, Annette M. Doherty, Jeremy J. Edmunds
-
Patent number: 5550110Abstract: Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders especially cerebral vasospasm, stroke, and head injury, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes.Type: GrantFiled: June 30, 1994Date of Patent: August 27, 1996Assignee: Warner-Lambert CompanyInventors: Wayne L. Cody, Annette M. Doherty, John G. Topliss
-
Patent number: 5482960Abstract: Novel indole and indoline nonpeptide antagonists of endothelin I are described, as well as novel intermediates used in their preparation, methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure and subarachnoid hemorrhage.Type: GrantFiled: November 14, 1994Date of Patent: January 9, 1996Assignee: Warner-Lambert CompanyInventors: Kent A. Berryman, Amy M. Bunker, Annette M. Doherty, Jeremy J. Edmunds
-
Patent number: 5453488Abstract: The invention concerns novel renin-inhibitory compounds which contain an amino-substituted heterocycle at the P.sub.2 position. These are useful for treating renin-associated hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.Type: GrantFiled: March 26, 1993Date of Patent: September 26, 1995Assignee: Warner-Lambert CompanyInventors: Cleo Connolly, Annette M. Doherty, Harriet W. Hamilton, William C. Patt, Ila Sircar
-
Patent number: 5382569Abstract: Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, Raynaud's disease, percutaneous transluminal coronary angioplasty or restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, ischemic bowel disease, and diabetes.Type: GrantFiled: December 21, 1992Date of Patent: January 17, 1995Assignee: Warner-Lambert CompanyInventors: Wayne L. Cody, Patricia DePue, Annette M. Doherty, John X. He, Michael D. Taylor
-
Patent number: 5288851Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.Type: GrantFiled: August 4, 1992Date of Patent: February 22, 1994Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Harriet W. Hamilton, John C. Hodges, Joseph T. Repine, Ila Sircar
-
Patent number: 5260276Abstract: Novel linear and monocyclic antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling hypertension, myocardial infarction, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute renal failure, preeclampsia, and diabetes.Type: GrantFiled: June 14, 1991Date of Patent: November 9, 1993Assignee: Warner-Lambert CompanyInventors: Wayne L. Cody, Annette M. Doherty, John X. He
-
Patent number: 5238923Abstract: The invention concerns novel renin-inhibitory compounds which contain an amino-substituted heterocycle at the P.sub.2 position. These are useful for treating renin-associated hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.Type: GrantFiled: April 25, 1990Date of Patent: August 24, 1993Assignee: Warner-Lambert CompanyInventors: Cleo Connolly, Annette M. Doherty, Harriet W. Hamilton, William C. Patt, Ila Sircar
-
Patent number: 5162527Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.Type: GrantFiled: March 27, 1991Date of Patent: November 10, 1992Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Harriet W. Hamilton, John C. Hodges, Joseph T. Repine, Ila Sircar
-
Patent number: 5149692Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, glaucoma, and diseases caused by retroviruses including HTLV-I, -II, -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.Type: GrantFiled: December 21, 1989Date of Patent: September 22, 1992Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Harriet W. Hamilton, Bruce A. Steinbaugh
-
Patent number: 5071837Abstract: The invention concerns certain orally active novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and glaucoma. It is also useful for treating diseases caused by retroviruses including HTLV-I, -II, and -III. Process for preparing the peptides, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.Type: GrantFiled: November 28, 1990Date of Patent: December 10, 1991Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Ila Sircar
-
Patent number: 5063207Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.Type: GrantFiled: July 24, 1989Date of Patent: November 5, 1991Assignee: Warner-Lambert CompanyInventors: Annette M. Doherty, Harriet W. Hamilton, John C. Hodges, Joseph T. Repine, Ila Sircar